| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Veterans | 95 | 2024 | 2631 | 6.080 |
Why?
|
| Cardiovascular Diseases | 148 | 2024 | 15399 | 3.880 |
Why?
|
| Antioxidants | 45 | 2020 | 1662 | 3.170 |
Why?
|
| Aspirin | 52 | 2022 | 3131 | 2.870 |
Why?
|
| Vitamin E | 31 | 2022 | 870 | 2.660 |
Why?
|
| Vitamins | 27 | 2022 | 1632 | 2.630 |
Why?
|
| beta Carotene | 51 | 2018 | 523 | 2.520 |
Why?
|
| Physicians | 81 | 2022 | 4580 | 2.290 |
Why?
|
| Heart Failure | 57 | 2024 | 11593 | 2.240 |
Why?
|
| Genome-Wide Association Study | 83 | 2024 | 12604 | 2.240 |
Why?
|
| Alcohol Drinking | 46 | 2024 | 4018 | 2.210 |
Why?
|
| Ascorbic Acid | 18 | 2022 | 655 | 2.130 |
Why?
|
| Dietary Supplements | 36 | 2022 | 3387 | 2.060 |
Why?
|
| Hypertension | 59 | 2022 | 8499 | 2.030 |
Why?
|
| Risk Factors | 309 | 2024 | 73809 | 1.940 |
Why?
|
| Cholesterol, HDL | 23 | 2024 | 1808 | 1.880 |
Why?
|
| Diet | 55 | 2024 | 8005 | 1.750 |
Why?
|
| Aged | 406 | 2024 | 168218 | 1.720 |
Why?
|
| Myocardial Infarction | 65 | 2024 | 11424 | 1.680 |
Why?
|
| Eggs | 7 | 2022 | 183 | 1.600 |
Why?
|
| Carotenoids | 24 | 2008 | 620 | 1.600 |
Why?
|
| Middle Aged | 442 | 2024 | 219568 | 1.590 |
Why?
|
| Polymorphism, Single Nucleotide | 91 | 2024 | 15773 | 1.550 |
Why?
|
| Coronary Disease | 27 | 2023 | 5917 | 1.520 |
Why?
|
| Cholesterol | 26 | 2023 | 2902 | 1.500 |
Why?
|
| Body Mass Index | 62 | 2024 | 12876 | 1.490 |
Why?
|
| Male | 492 | 2024 | 358747 | 1.460 |
Why?
|
| Prospective Studies | 198 | 2024 | 54137 | 1.450 |
Why?
|
| Genetic Predisposition to Disease | 82 | 2024 | 17768 | 1.380 |
Why?
|
| Proportional Hazards Models | 95 | 2024 | 12440 | 1.370 |
Why?
|
| Blood Pressure | 37 | 2024 | 8451 | 1.360 |
Why?
|
| Humans | 687 | 2024 | 758406 | 1.330 |
Why?
|
| Prostatic Neoplasms | 55 | 2024 | 11336 | 1.310 |
Why?
|
| Bromocriptine | 4 | 2015 | 93 | 1.310 |
Why?
|
| United States Department of Veterans Affairs | 27 | 2024 | 907 | 1.310 |
Why?
|
| Diabetes Mellitus, Type 2 | 43 | 2024 | 12075 | 1.290 |
Why?
|
| United States | 204 | 2024 | 72136 | 1.280 |
Why?
|
| Fatty Acids, Monounsaturated | 8 | 2020 | 190 | 1.260 |
Why?
|
| Pancreatic Neoplasms | 32 | 2024 | 5349 | 1.240 |
Why?
|
| Nuts | 9 | 2021 | 263 | 1.230 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 19 | 2022 | 2269 | 1.220 |
Why?
|
| Coronary Artery Disease | 29 | 2023 | 6362 | 1.210 |
Why?
|
| Stroke | 46 | 2024 | 9694 | 1.200 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 16 | 2023 | 3227 | 1.200 |
Why?
|
| Case-Control Studies | 121 | 2024 | 22029 | 1.200 |
Why?
|
| Cohort Studies | 139 | 2024 | 41256 | 1.170 |
Why?
|
| Aged, 80 and over | 164 | 2024 | 58683 | 1.150 |
Why?
|
| Randomized Controlled Trials as Topic | 76 | 2020 | 10146 | 1.140 |
Why?
|
| Follow-Up Studies | 120 | 2021 | 39059 | 1.130 |
Why?
|
| Incidence | 95 | 2024 | 21272 | 1.130 |
Why?
|
| Veterans Health | 7 | 2021 | 215 | 1.100 |
Why?
|
| Cholesterol, LDL | 19 | 2024 | 2374 | 1.090 |
Why?
|
| Risk Assessment | 84 | 2024 | 23884 | 1.080 |
Why?
|
| Double-Blind Method | 70 | 2022 | 12262 | 1.070 |
Why?
|
| Risk | 63 | 2021 | 9599 | 1.050 |
Why?
|
| Macular Degeneration | 7 | 2020 | 1001 | 1.040 |
Why?
|
| Lipids | 22 | 2024 | 3326 | 1.000 |
Why?
|
| Homocysteine | 12 | 2017 | 638 | 0.990 |
Why?
|
| Mendelian Randomization Analysis | 13 | 2024 | 993 | 0.980 |
Why?
|
| Life Style | 33 | 2023 | 3886 | 0.980 |
Why?
|
| Smoking | 48 | 2024 | 9051 | 0.970 |
Why?
|
| Fatty Acids, Omega-3 | 11 | 2023 | 1373 | 0.960 |
Why?
|
| Platelet Aggregation Inhibitors | 11 | 2018 | 2747 | 0.950 |
Why?
|
| Female | 326 | 2024 | 390323 | 0.860 |
Why?
|
| Anticarcinogenic Agents | 7 | 2017 | 249 | 0.860 |
Why?
|
| Primary Prevention | 9 | 2019 | 1185 | 0.850 |
Why?
|
| Cholesterol, Dietary | 8 | 2010 | 223 | 0.840 |
Why?
|
| Oleic Acids | 2 | 2013 | 74 | 0.830 |
Why?
|
| Phospholipids | 6 | 2017 | 784 | 0.800 |
Why?
|
| Cardiology | 7 | 2021 | 1667 | 0.790 |
Why?
|
| Analgesics, Non-Narcotic | 4 | 2006 | 370 | 0.770 |
Why?
|
| Multivariate Analysis | 50 | 2021 | 12096 | 0.740 |
Why?
|
| Dopamine Agonists | 3 | 2015 | 352 | 0.740 |
Why?
|
| Adult | 214 | 2024 | 219935 | 0.730 |
Why?
|
| Blood Component Transfusion | 1 | 2021 | 141 | 0.730 |
Why?
|
| Cataract | 6 | 2015 | 827 | 0.720 |
Why?
|
| Odds Ratio | 42 | 2021 | 9650 | 0.690 |
Why?
|
| Hypercholesterolemia | 14 | 2018 | 1138 | 0.690 |
Why?
|
| Risk Reduction Behavior | 8 | 2019 | 1098 | 0.690 |
Why?
|
| Neoplasms | 45 | 2023 | 22032 | 0.670 |
Why?
|
| Immunization, Passive | 1 | 2021 | 616 | 0.650 |
Why?
|
| Dyslipidemias | 4 | 2012 | 867 | 0.640 |
Why?
|
| Solanum tuberosum | 3 | 2024 | 40 | 0.630 |
Why?
|
| Aging | 15 | 2022 | 8650 | 0.630 |
Why?
|
| Electronic Health Records | 18 | 2024 | 4761 | 0.620 |
Why?
|
| Military Personnel | 5 | 2024 | 1244 | 0.620 |
Why?
|
| C-Reactive Protein | 16 | 2023 | 3812 | 0.620 |
Why?
|
| Cholangiocarcinoma | 6 | 2020 | 550 | 0.610 |
Why?
|
| Fatty Acids, Unsaturated | 5 | 2020 | 540 | 0.610 |
Why?
|
| Bile Duct Neoplasms | 6 | 2019 | 602 | 0.610 |
Why?
|
| Plasma | 1 | 2021 | 584 | 0.610 |
Why?
|
| Folic Acid | 12 | 2018 | 1309 | 0.600 |
Why?
|
| Confidence Intervals | 20 | 2019 | 2925 | 0.590 |
Why?
|
| Gonadal Steroid Hormones | 9 | 2020 | 701 | 0.590 |
Why?
|
| Genotype | 46 | 2023 | 12945 | 0.590 |
Why?
|
| Warfarin | 2 | 2016 | 1482 | 0.590 |
Why?
|
| Anticholesteremic Agents | 8 | 2013 | 963 | 0.580 |
Why?
|
| Vitamin B 6 | 6 | 2019 | 233 | 0.580 |
Why?
|
| Hyperlipidemias | 7 | 2018 | 772 | 0.580 |
Why?
|
| Selenium | 9 | 2020 | 416 | 0.570 |
Why?
|
| Quantitative Trait Loci | 9 | 2024 | 2100 | 0.570 |
Why?
|
| Glomerular Filtration Rate | 16 | 2024 | 2154 | 0.570 |
Why?
|
| Seafood | 4 | 2019 | 390 | 0.570 |
Why?
|
| Renal Insufficiency, Chronic | 9 | 2023 | 2239 | 0.570 |
Why?
|
| Logistic Models | 39 | 2018 | 13276 | 0.570 |
Why?
|
| Biological Specimen Banks | 4 | 2024 | 782 | 0.560 |
Why?
|
| Obesity | 28 | 2023 | 12870 | 0.560 |
Why?
|
| Atrial Fibrillation | 12 | 2023 | 5103 | 0.540 |
Why?
|
| Diabetes Mellitus | 18 | 2023 | 5816 | 0.540 |
Why?
|
| Cardiac Output, Low | 2 | 2007 | 191 | 0.540 |
Why?
|
| Motor Activity | 8 | 2015 | 2685 | 0.530 |
Why?
|
| Cacao | 5 | 2015 | 98 | 0.520 |
Why?
|
| Cause of Death | 23 | 2024 | 3675 | 0.520 |
Why?
|
| Galectin 3 | 2 | 2016 | 240 | 0.510 |
Why?
|
| Self Report | 16 | 2024 | 3714 | 0.510 |
Why?
|
| Overweight | 11 | 2015 | 2411 | 0.500 |
Why?
|
| Triglycerides | 12 | 2013 | 2451 | 0.500 |
Why?
|
| Aminoacyltransferases | 1 | 2015 | 50 | 0.500 |
Why?
|
| Health Status | 12 | 2024 | 4071 | 0.500 |
Why?
|
| Dietary Fats | 9 | 2023 | 1991 | 0.500 |
Why?
|
| Kidney Diseases | 7 | 2011 | 2083 | 0.490 |
Why?
|
| alpha-Tocopherol | 8 | 2017 | 126 | 0.490 |
Why?
|
| Health Behavior | 9 | 2015 | 2617 | 0.490 |
Why?
|
| Antihypertensive Agents | 7 | 2021 | 2016 | 0.480 |
Why?
|
| Coffee | 5 | 2020 | 582 | 0.480 |
Why?
|
| Vitamin D | 10 | 2019 | 3283 | 0.470 |
Why?
|
| alpha-Linolenic Acid | 2 | 2014 | 144 | 0.460 |
Why?
|
| Exercise | 16 | 2024 | 5788 | 0.450 |
Why?
|
| Forecasting | 4 | 2018 | 2923 | 0.450 |
Why?
|
| Cholesterol, VLDL | 1 | 2013 | 70 | 0.450 |
Why?
|
| Kidney | 13 | 2023 | 7016 | 0.440 |
Why?
|
| Persian Gulf Syndrome | 2 | 2024 | 47 | 0.440 |
Why?
|
| Men's Health | 3 | 2017 | 73 | 0.440 |
Why?
|
| Apolipoprotein E4 | 4 | 2024 | 706 | 0.430 |
Why?
|
| Intracranial Hemorrhages | 3 | 2016 | 820 | 0.430 |
Why?
|
| Kynurenine | 4 | 2023 | 139 | 0.420 |
Why?
|
| Mortality | 13 | 2023 | 2886 | 0.420 |
Why?
|
| Adiponectin | 3 | 2013 | 1114 | 0.420 |
Why?
|
| Diabetes Complications | 11 | 2020 | 1317 | 0.420 |
Why?
|
| Gulf War | 4 | 2024 | 33 | 0.420 |
Why?
|
| Eating | 4 | 2012 | 1536 | 0.410 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 9 | 2014 | 415 | 0.410 |
Why?
|
| Hormone Antagonists | 1 | 2012 | 108 | 0.410 |
Why?
|
| Vitamin B Complex | 6 | 2017 | 297 | 0.410 |
Why?
|
| Plaque, Atherosclerotic | 6 | 2023 | 1505 | 0.410 |
Why?
|
| Cardiomyopathies | 3 | 2023 | 1944 | 0.410 |
Why?
|
| Heptanoic Acids | 2 | 2011 | 344 | 0.400 |
Why?
|
| Hyperglycemia | 4 | 2015 | 1368 | 0.400 |
Why?
|
| Liver Neoplasms | 8 | 2020 | 4313 | 0.400 |
Why?
|
| Fishes | 6 | 2019 | 601 | 0.400 |
Why?
|
| Marijuana Abuse | 2 | 2023 | 410 | 0.390 |
Why?
|
| Genetic Loci | 10 | 2024 | 2612 | 0.390 |
Why?
|
| Eicosapentaenoic Acid | 2 | 2023 | 560 | 0.380 |
Why?
|
| Stress Disorders, Post-Traumatic | 7 | 2024 | 4560 | 0.380 |
Why?
|
| Vitamin A | 5 | 2017 | 613 | 0.370 |
Why?
|
| Polymorphism, Genetic | 15 | 2022 | 4284 | 0.370 |
Why?
|
| Fatty Acids, Omega-6 | 3 | 2020 | 226 | 0.370 |
Why?
|
| Acetaminophen | 6 | 2022 | 552 | 0.370 |
Why?
|
| Erythrocyte Membrane | 1 | 2012 | 439 | 0.360 |
Why?
|
| Frail Elderly | 6 | 2024 | 751 | 0.360 |
Why?
|
| Atherosclerosis | 6 | 2023 | 3401 | 0.360 |
Why?
|
| Chromosomes, Human, X | 3 | 2024 | 321 | 0.360 |
Why?
|
| Carbon | 4 | 2021 | 667 | 0.360 |
Why?
|
| Inflammation Mediators | 3 | 2015 | 1878 | 0.360 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 5 | 2023 | 321 | 0.350 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2012 | 296 | 0.350 |
Why?
|
| Biomedical Technology | 1 | 2012 | 209 | 0.350 |
Why?
|
| Deglutition Disorders | 6 | 2016 | 625 | 0.350 |
Why?
|
| Lipoproteins, LDL | 6 | 2011 | 640 | 0.350 |
Why?
|
| Comorbidity | 23 | 2022 | 10495 | 0.350 |
Why?
|
| Carcinoma, Large Cell | 3 | 2019 | 113 | 0.350 |
Why?
|
| Genetic Association Studies | 12 | 2024 | 2717 | 0.350 |
Why?
|
| Cystatins | 2 | 2021 | 55 | 0.350 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2012 | 485 | 0.350 |
Why?
|
| Insulin-Like Growth Factor I | 9 | 2014 | 1927 | 0.340 |
Why?
|
| Influenza, Human | 4 | 2022 | 1516 | 0.340 |
Why?
|
| Cicatrix | 1 | 2015 | 781 | 0.340 |
Why?
|
| Cognition Disorders | 7 | 2019 | 3975 | 0.340 |
Why?
|
| Chromosomes, Human, Pair 5 | 4 | 2016 | 385 | 0.340 |
Why?
|
| Cyclooxygenase Inhibitors | 5 | 2012 | 361 | 0.340 |
Why?
|
| Feeding Behavior | 12 | 2014 | 3184 | 0.340 |
Why?
|
| Brain Ischemia | 11 | 2011 | 3047 | 0.330 |
Why?
|
| Evidence-Based Medicine | 4 | 2016 | 3671 | 0.330 |
Why?
|
| Fasting | 5 | 2012 | 1599 | 0.330 |
Why?
|
| Trans Fatty Acids | 3 | 2023 | 155 | 0.330 |
Why?
|
| Venous Thromboembolism | 4 | 2023 | 1855 | 0.330 |
Why?
|
| Kidney Failure, Chronic | 7 | 2024 | 2457 | 0.320 |
Why?
|
| Lovastatin | 3 | 2011 | 116 | 0.320 |
Why?
|
| Influenza Vaccines | 3 | 2022 | 759 | 0.320 |
Why?
|
| Cognition | 8 | 2019 | 6953 | 0.320 |
Why?
|
| Medication Adherence | 3 | 2020 | 2155 | 0.320 |
Why?
|
| Meat | 4 | 2024 | 584 | 0.320 |
Why?
|
| Docosahexaenoic Acids | 2 | 2023 | 905 | 0.310 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2020 | 2292 | 0.310 |
Why?
|
| Epidemiology | 2 | 2010 | 279 | 0.310 |
Why?
|
| Alzheimer Disease | 5 | 2024 | 8544 | 0.310 |
Why?
|
| Adenocarcinoma | 10 | 2021 | 6313 | 0.310 |
Why?
|
| Physical Fitness | 3 | 2019 | 732 | 0.310 |
Why?
|
| Lung Neoplasms | 13 | 2023 | 13245 | 0.300 |
Why?
|
| Hyperlipoproteinemia Type II | 2 | 2024 | 393 | 0.300 |
Why?
|
| Fruit | 7 | 2017 | 1160 | 0.300 |
Why?
|
| Vegetables | 7 | 2017 | 1195 | 0.300 |
Why?
|
| Time Factors | 32 | 2021 | 39872 | 0.300 |
Why?
|
| Pyrroles | 2 | 2011 | 1130 | 0.300 |
Why?
|
| Epidemiologic Studies | 2 | 2010 | 670 | 0.300 |
Why?
|
| Treatment Outcome | 36 | 2022 | 64378 | 0.290 |
Why?
|
| Research Design | 12 | 2018 | 6157 | 0.290 |
Why?
|
| Alcoholism | 4 | 2023 | 1962 | 0.290 |
Why?
|
| Renal Insufficiency | 2 | 2005 | 809 | 0.290 |
Why?
|
| Dementia | 3 | 2024 | 2650 | 0.290 |
Why?
|
| Diet, Mediterranean | 3 | 2021 | 736 | 0.290 |
Why?
|
| Inflammation | 11 | 2023 | 10718 | 0.290 |
Why?
|
| Pravastatin | 3 | 2011 | 392 | 0.290 |
Why?
|
| Hospitalization | 14 | 2022 | 10652 | 0.280 |
Why?
|
| Linear Models | 8 | 2019 | 5862 | 0.280 |
Why?
|
| Intention to Treat Analysis | 3 | 2021 | 414 | 0.280 |
Why?
|
| International Classification of Diseases | 3 | 2021 | 892 | 0.280 |
Why?
|
| Mosaicism | 3 | 2016 | 465 | 0.280 |
Why?
|
| Peripheral Arterial Disease | 4 | 2021 | 1246 | 0.280 |
Why?
|
| Longitudinal Studies | 16 | 2024 | 14490 | 0.280 |
Why?
|
| C-Peptide | 5 | 2012 | 433 | 0.280 |
Why?
|
| Multiple Myeloma | 5 | 2024 | 5129 | 0.280 |
Why?
|
| Women's Health | 8 | 2021 | 2057 | 0.280 |
Why?
|
| Sex Hormone-Binding Globulin | 5 | 2020 | 546 | 0.280 |
Why?
|
| Health Surveys | 10 | 2024 | 4064 | 0.280 |
Why?
|
| Hypolipidemic Agents | 2 | 2009 | 609 | 0.280 |
Why?
|
| Retrospective Studies | 41 | 2024 | 80168 | 0.270 |
Why?
|
| Vascular Diseases | 5 | 2019 | 1160 | 0.270 |
Why?
|
| Stroke Volume | 9 | 2024 | 5460 | 0.270 |
Why?
|
| Creatinine | 8 | 2022 | 1892 | 0.270 |
Why?
|
| Phenotype | 18 | 2024 | 16534 | 0.270 |
Why?
|
| Interleukin-6 | 5 | 2015 | 3208 | 0.270 |
Why?
|
| Glioma | 7 | 2015 | 3418 | 0.260 |
Why?
|
| Coronary Vessels | 7 | 2023 | 3072 | 0.260 |
Why?
|
| Ventricular Dysfunction, Left | 4 | 2022 | 2115 | 0.260 |
Why?
|
| Alcoholic Beverages | 4 | 2023 | 264 | 0.260 |
Why?
|
| Genomics | 5 | 2022 | 5790 | 0.260 |
Why?
|
| Bipolar Disorder | 5 | 2024 | 5079 | 0.260 |
Why?
|
| Restless Legs Syndrome | 3 | 2013 | 233 | 0.250 |
Why?
|
| Genetic Variation | 13 | 2024 | 6548 | 0.250 |
Why?
|
| Diet Surveys | 6 | 2014 | 1161 | 0.250 |
Why?
|
| Age Factors | 23 | 2022 | 18358 | 0.250 |
Why?
|
| Cooking | 2 | 2019 | 311 | 0.250 |
Why?
|
| Anthropometry | 4 | 2019 | 1347 | 0.250 |
Why?
|
| Blood Glucose | 8 | 2019 | 6346 | 0.250 |
Why?
|
| Enzyme Inhibitors | 2 | 2015 | 3709 | 0.250 |
Why?
|
| Candy | 2 | 2014 | 36 | 0.240 |
Why?
|
| Ethanol | 4 | 2014 | 1323 | 0.240 |
Why?
|
| Visual Acuity | 6 | 2017 | 2642 | 0.240 |
Why?
|
| Body Height | 5 | 2018 | 1567 | 0.240 |
Why?
|
| ABO Blood-Group System | 4 | 2013 | 367 | 0.240 |
Why?
|
| Cross-Sectional Studies | 28 | 2024 | 25956 | 0.240 |
Why?
|
| Prognosis | 28 | 2019 | 29557 | 0.240 |
Why?
|
| Food Analysis | 1 | 2005 | 103 | 0.240 |
Why?
|
| Natural Language Processing | 3 | 2024 | 1134 | 0.240 |
Why?
|
| Erythrocytes | 4 | 2015 | 2413 | 0.240 |
Why?
|
| Algorithms | 12 | 2024 | 13961 | 0.240 |
Why?
|
| Awareness | 1 | 2009 | 644 | 0.240 |
Why?
|
| Marijuana Smoking | 1 | 2008 | 258 | 0.240 |
Why?
|
| Europe | 11 | 2021 | 3420 | 0.240 |
Why?
|
| Tocopherols | 3 | 2014 | 44 | 0.230 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2021 | 1724 | 0.230 |
Why?
|
| Prevalence | 19 | 2021 | 15651 | 0.230 |
Why?
|
| Family Health | 2 | 2008 | 1257 | 0.230 |
Why?
|
| Heart Diseases | 2 | 2018 | 2782 | 0.230 |
Why?
|
| Schizophrenia | 5 | 2024 | 6910 | 0.230 |
Why?
|
| Vietnam Conflict | 1 | 2024 | 100 | 0.230 |
Why?
|
| Lipoproteins, HDL | 4 | 2011 | 664 | 0.230 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2019 | 419 | 0.230 |
Why?
|
| Waist Circumference | 6 | 2019 | 921 | 0.230 |
Why?
|
| Epiretinal Membrane | 1 | 2024 | 73 | 0.230 |
Why?
|
| Gout | 2 | 2022 | 618 | 0.230 |
Why?
|
| Bile Ducts, Intrahepatic | 4 | 2020 | 296 | 0.230 |
Why?
|
| Blood Pressure Determination | 1 | 2007 | 634 | 0.220 |
Why?
|
| Self Disclosure | 1 | 2005 | 249 | 0.220 |
Why?
|
| Survival Rate | 14 | 2018 | 12721 | 0.220 |
Why?
|
| Erectile Dysfunction | 1 | 2007 | 451 | 0.220 |
Why?
|
| Geriatric Assessment | 5 | 2024 | 1404 | 0.220 |
Why?
|
| Cotinine | 3 | 2018 | 203 | 0.220 |
Why?
|
| Saphenous Vein | 2 | 2018 | 517 | 0.220 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2018 | 373 | 0.220 |
Why?
|
| Dietary Fats, Unsaturated | 3 | 2020 | 224 | 0.220 |
Why?
|
| Sodium | 2 | 2019 | 1588 | 0.220 |
Why?
|
| Coronary Artery Bypass | 5 | 2019 | 2189 | 0.210 |
Why?
|
| Arteriosclerosis | 5 | 2000 | 1055 | 0.210 |
Why?
|
| Vitamin B 12 | 5 | 2008 | 522 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 5 | 2012 | 7378 | 0.210 |
Why?
|
| Epidemiologic Research Design | 2 | 2018 | 368 | 0.210 |
Why?
|
| Cardiotonic Agents | 1 | 2006 | 539 | 0.210 |
Why?
|
| Sex Factors | 14 | 2021 | 10504 | 0.210 |
Why?
|
| Chronic Disease | 14 | 2020 | 9267 | 0.210 |
Why?
|
| Alleles | 13 | 2023 | 6895 | 0.210 |
Why?
|
| Predictive Value of Tests | 14 | 2019 | 15225 | 0.200 |
Why?
|
| Hypoglycemic Agents | 3 | 2020 | 3069 | 0.200 |
Why?
|
| Patient Compliance | 5 | 2018 | 2685 | 0.200 |
Why?
|
| Fuchs' Endothelial Dystrophy | 1 | 2024 | 100 | 0.200 |
Why?
|
| Death, Sudden, Cardiac | 4 | 2019 | 1554 | 0.200 |
Why?
|
| Lipid Metabolism | 3 | 2018 | 1895 | 0.200 |
Why?
|
| Sickle Cell Trait | 1 | 2022 | 85 | 0.200 |
Why?
|
| Reference Values | 6 | 2017 | 4919 | 0.200 |
Why?
|
| Mental Health | 2 | 2022 | 3234 | 0.190 |
Why?
|
| Telomerase | 3 | 2016 | 745 | 0.190 |
Why?
|
| Amyotrophic Lateral Sclerosis | 3 | 2018 | 1463 | 0.190 |
Why?
|
| Linkage Disequilibrium | 9 | 2021 | 1996 | 0.190 |
Why?
|
| Sex Distribution | 6 | 2019 | 2284 | 0.190 |
Why?
|
| Models, Theoretical | 1 | 2013 | 3561 | 0.190 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2024 | 273 | 0.190 |
Why?
|
| Receptors, Somatostatin | 2 | 2014 | 136 | 0.190 |
Why?
|
| Chromosome Mapping | 4 | 2024 | 4624 | 0.190 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2024 | 226 | 0.190 |
Why?
|
| Telomere | 3 | 2019 | 931 | 0.190 |
Why?
|
| Alanine Transaminase | 2 | 2022 | 604 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2016 | 635 | 0.190 |
Why?
|
| Postmenopause | 6 | 2020 | 2509 | 0.190 |
Why?
|
| Age Distribution | 8 | 2009 | 2882 | 0.190 |
Why?
|
| Gene Frequency | 6 | 2020 | 3612 | 0.190 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 5 | 2012 | 275 | 0.180 |
Why?
|
| Anticoagulants | 1 | 2016 | 4777 | 0.180 |
Why?
|
| Genetic Markers | 4 | 2020 | 2608 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2016 | 452 | 0.180 |
Why?
|
| Pain | 2 | 2006 | 5065 | 0.180 |
Why?
|
| Disease Progression | 15 | 2024 | 13468 | 0.180 |
Why?
|
| Parkinson Disease | 6 | 2013 | 2862 | 0.180 |
Why?
|
| Health Services | 1 | 2006 | 752 | 0.180 |
Why?
|
| Ticlopidine | 2 | 2015 | 731 | 0.180 |
Why?
|
| Simvastatin | 3 | 2011 | 351 | 0.180 |
Why?
|
| Estrogen Receptor beta | 3 | 2020 | 168 | 0.180 |
Why?
|
| Linoleic Acid | 2 | 2019 | 158 | 0.180 |
Why?
|
| Carcinoma | 4 | 2016 | 2330 | 0.180 |
Why?
|
| Verbal Behavior | 1 | 2001 | 335 | 0.180 |
Why?
|
| Azithromycin | 1 | 2021 | 200 | 0.180 |
Why?
|
| Longevity | 1 | 2008 | 1050 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2019 | 4023 | 0.170 |
Why?
|
| Drug Therapy, Combination | 9 | 2021 | 6293 | 0.170 |
Why?
|
| Up-Regulation | 4 | 2018 | 4113 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2021 | 313 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2013 | 3801 | 0.170 |
Why?
|
| Acute Kidney Injury | 2 | 2022 | 1926 | 0.170 |
Why?
|
| Fatty Acids | 4 | 2023 | 1803 | 0.170 |
Why?
|
| Angioplasty, Balloon, Coronary | 4 | 2019 | 1730 | 0.170 |
Why?
|
| Regression Analysis | 10 | 2021 | 6354 | 0.170 |
Why?
|
| Occupational Exposure | 3 | 2024 | 1809 | 0.170 |
Why?
|
| Glycine Hydroxymethyltransferase | 2 | 2012 | 32 | 0.170 |
Why?
|
| Cataract Extraction | 3 | 2015 | 465 | 0.170 |
Why?
|
| Angina Pectoris | 4 | 2016 | 958 | 0.160 |
Why?
|
| Body Weight | 6 | 2018 | 4603 | 0.160 |
Why?
|
| Cerebral Hemorrhage | 5 | 2006 | 2650 | 0.160 |
Why?
|
| Patient Selection | 8 | 2012 | 4244 | 0.160 |
Why?
|
| Puerperal Disorders | 1 | 2022 | 299 | 0.160 |
Why?
|
| Biomedical Research | 2 | 2016 | 3418 | 0.160 |
Why?
|
| Patient Admission | 2 | 2019 | 1372 | 0.160 |
Why?
|
| Drug Repositioning | 1 | 2021 | 231 | 0.160 |
Why?
|
| Leukocytes | 4 | 2020 | 2025 | 0.160 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2020 | 190 | 0.160 |
Why?
|
| Life Expectancy | 3 | 2023 | 1244 | 0.160 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2019 | 89 | 0.160 |
Why?
|
| Drug Combinations | 4 | 2015 | 2020 | 0.160 |
Why?
|
| Reproducibility of Results | 10 | 2021 | 20055 | 0.160 |
Why?
|
| Drug Interactions | 3 | 2016 | 1414 | 0.160 |
Why?
|
| Receptors, LDL | 4 | 2024 | 485 | 0.160 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2019 | 278 | 0.160 |
Why?
|
| Sodium, Dietary | 1 | 2022 | 425 | 0.150 |
Why?
|
| Kidney Function Tests | 4 | 2019 | 677 | 0.150 |
Why?
|
| Severity of Illness Index | 10 | 2016 | 15785 | 0.150 |
Why?
|
| Gallbladder Neoplasms | 1 | 2019 | 190 | 0.150 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 2 | 2010 | 206 | 0.150 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2023 | 615 | 0.150 |
Why?
|
| Neoplasm Staging | 8 | 2024 | 11152 | 0.150 |
Why?
|
| Respiratory Aspiration | 2 | 2016 | 89 | 0.150 |
Why?
|
| Inheritance Patterns | 2 | 2019 | 340 | 0.150 |
Why?
|
| Hypertriglyceridemia | 2 | 2007 | 293 | 0.150 |
Why?
|
| Receptors, Calcitriol | 2 | 2012 | 359 | 0.150 |
Why?
|
| Arachidonic Acid | 1 | 2019 | 427 | 0.150 |
Why?
|
| Head and Neck Neoplasms | 5 | 2015 | 2882 | 0.150 |
Why?
|
| Metabolism | 1 | 2019 | 193 | 0.150 |
Why?
|
| Oleic Acid | 1 | 2017 | 92 | 0.150 |
Why?
|
| Ventricular Function, Left | 5 | 2023 | 3858 | 0.150 |
Why?
|
| Selenomethionine | 2 | 2015 | 17 | 0.150 |
Why?
|
| Hydroxychloroquine | 1 | 2021 | 426 | 0.140 |
Why?
|
| Multicenter Studies as Topic | 5 | 2021 | 1705 | 0.140 |
Why?
|
| Colorectal Neoplasms | 7 | 2018 | 6852 | 0.140 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2019 | 184 | 0.140 |
Why?
|
| Uric Acid | 2 | 2022 | 803 | 0.140 |
Why?
|
| Flavonoids | 3 | 2014 | 443 | 0.140 |
Why?
|
| Chromatography, Gas | 2 | 2014 | 151 | 0.140 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2022 | 500 | 0.140 |
Why?
|
| Medical Records | 4 | 2013 | 1406 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 8506 | 0.140 |
Why?
|
| Carcinoma, Small Cell | 1 | 2019 | 416 | 0.140 |
Why?
|
| Resistance Training | 1 | 2018 | 185 | 0.130 |
Why?
|
| Analgesics | 1 | 2003 | 1064 | 0.130 |
Why?
|
| Tricarboxylic Acids | 1 | 2016 | 26 | 0.130 |
Why?
|
| Hormones | 1 | 2020 | 869 | 0.130 |
Why?
|
| Methionine | 2 | 2018 | 569 | 0.130 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2019 | 540 | 0.130 |
Why?
|
| Iron Regulatory Protein 1 | 1 | 2016 | 37 | 0.130 |
Why?
|
| Functional Food | 1 | 2015 | 19 | 0.130 |
Why?
|
| Hospice Care | 1 | 2022 | 677 | 0.130 |
Why?
|
| Cyclooxygenase 2 | 2 | 2009 | 597 | 0.130 |
Why?
|
| Elder Nutritional Physiological Phenomena | 1 | 2015 | 7 | 0.130 |
Why?
|
| Exercise Test | 1 | 2003 | 2121 | 0.130 |
Why?
|
| Nitroglycerin | 1 | 2016 | 328 | 0.130 |
Why?
|
| Soy Foods | 1 | 2015 | 44 | 0.130 |
Why?
|
| Walking | 2 | 2016 | 1188 | 0.130 |
Why?
|
| Receptors, Cytokine | 1 | 2016 | 258 | 0.120 |
Why?
|
| Placebos | 6 | 2010 | 1661 | 0.120 |
Why?
|
| Migraine with Aura | 2 | 2008 | 203 | 0.120 |
Why?
|
| Receptors, Leptin | 1 | 2016 | 350 | 0.120 |
Why?
|
| Diabetic Nephropathies | 1 | 2022 | 973 | 0.120 |
Why?
|
| Vaccines | 1 | 2023 | 832 | 0.120 |
Why?
|
| Epidemiologic Methods | 5 | 2011 | 1338 | 0.120 |
Why?
|
| Electric Countershock | 1 | 2018 | 533 | 0.120 |
Why?
|
| Sequence Analysis | 1 | 2015 | 240 | 0.120 |
Why?
|
| Television | 1 | 2018 | 409 | 0.120 |
Why?
|
| Insulin Resistance | 5 | 2014 | 3941 | 0.120 |
Why?
|
| Thrombosis | 3 | 2023 | 2929 | 0.120 |
Why?
|
| Australia | 5 | 2018 | 1276 | 0.120 |
Why?
|
| Multifactorial Inheritance | 4 | 2024 | 1365 | 0.120 |
Why?
|
| Prostate-Specific Antigen | 7 | 2023 | 2528 | 0.120 |
Why?
|
| Brain Neoplasms | 5 | 2013 | 8981 | 0.120 |
Why?
|
| Recovery of Function | 4 | 2022 | 2970 | 0.120 |
Why?
|
| Milk | 3 | 2022 | 443 | 0.120 |
Why?
|
| Myeloproliferative Disorders | 1 | 2020 | 606 | 0.120 |
Why?
|
| Muscle Strength | 1 | 2018 | 618 | 0.120 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2016 | 123 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2018 | 6493 | 0.120 |
Why?
|
| Bariatric Surgery | 1 | 2024 | 986 | 0.120 |
Why?
|
| Fibrinolysis | 1 | 2015 | 332 | 0.120 |
Why?
|
| Survival Analysis | 9 | 2021 | 10112 | 0.120 |
Why?
|
| Migraine Disorders | 4 | 2019 | 1694 | 0.120 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2015 | 1125 | 0.110 |
Why?
|
| X Chromosome Inactivation | 1 | 2016 | 226 | 0.110 |
Why?
|
| Insulin | 7 | 2019 | 6578 | 0.110 |
Why?
|
| Electrocardiography | 3 | 2016 | 6363 | 0.110 |
Why?
|
| Lipid Peroxides | 1 | 1993 | 74 | 0.110 |
Why?
|
| Breast Neoplasms | 10 | 2010 | 21017 | 0.110 |
Why?
|
| Diabetic Angiopathies | 3 | 2020 | 802 | 0.110 |
Why?
|
| Beer | 2 | 2008 | 134 | 0.110 |
Why?
|
| High-Throughput Screening Assays | 1 | 2019 | 933 | 0.110 |
Why?
|
| Suicidal Ideation | 1 | 2024 | 1430 | 0.110 |
Why?
|
| Young Adult | 13 | 2022 | 58808 | 0.110 |
Why?
|
| Vitamin B Deficiency | 1 | 2013 | 12 | 0.110 |
Why?
|
| Tryptophan | 3 | 2023 | 479 | 0.110 |
Why?
|
| Drug Administration Schedule | 7 | 2015 | 4839 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2018 | 10748 | 0.110 |
Why?
|
| Massachusetts | 5 | 2013 | 8823 | 0.110 |
Why?
|
| Aortic Aneurysm | 1 | 2018 | 648 | 0.110 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 2 | 2020 | 54 | 0.110 |
Why?
|
| History, 20th Century | 2 | 2012 | 2772 | 0.110 |
Why?
|
| Deglutition | 3 | 2018 | 208 | 0.110 |
Why?
|
| Wine | 2 | 2008 | 166 | 0.110 |
Why?
|
| Body Size | 2 | 2014 | 462 | 0.110 |
Why?
|
| Chemoprevention | 1 | 1996 | 326 | 0.110 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2015 | 418 | 0.110 |
Why?
|
| Preventive Medicine | 1 | 2015 | 247 | 0.110 |
Why?
|
| DNA Methylation | 4 | 2016 | 4373 | 0.110 |
Why?
|
| Venous Thrombosis | 1 | 2023 | 1292 | 0.110 |
Why?
|
| Fractures, Bone | 1 | 2005 | 2040 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 4 | 2019 | 2690 | 0.110 |
Why?
|
| Central Nervous System Depressants | 1 | 2014 | 164 | 0.110 |
Why?
|
| Antineoplastic Agents | 3 | 2023 | 13591 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 3 | 2021 | 7403 | 0.110 |
Why?
|
| Hypersensitivity | 2 | 2013 | 1155 | 0.110 |
Why?
|
| Mental Disorders | 2 | 2019 | 6803 | 0.110 |
Why?
|
| Iron | 1 | 2021 | 1786 | 0.110 |
Why?
|
| Pyridoxine | 3 | 2007 | 108 | 0.110 |
Why?
|
| Hemorrhage | 3 | 2019 | 3400 | 0.110 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 682 | 0.110 |
Why?
|
| Cardiovascular Agents | 1 | 2019 | 839 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2019 | 3217 | 0.100 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2012 | 8 | 0.100 |
Why?
|
| Mississippi | 3 | 2018 | 93 | 0.100 |
Why?
|
| Kidney Neoplasms | 3 | 2019 | 4312 | 0.100 |
Why?
|
| Hemoglobins | 3 | 2022 | 1519 | 0.100 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2012 | 92 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 2 | 1997 | 1826 | 0.100 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2012 | 68 | 0.100 |
Why?
|
| Dairy Products | 3 | 2017 | 491 | 0.100 |
Why?
|
| Estrogen Receptor alpha | 3 | 2020 | 580 | 0.100 |
Why?
|
| Anti-Infective Agents | 1 | 1999 | 981 | 0.100 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2013 | 131 | 0.100 |
Why?
|
| Obesity, Abdominal | 1 | 2015 | 374 | 0.100 |
Why?
|
| Asthma | 3 | 2011 | 6172 | 0.100 |
Why?
|
| Membrane Proteins | 5 | 2022 | 7843 | 0.100 |
Why?
|
| Copper | 2 | 1993 | 366 | 0.100 |
Why?
|
| Mannose-Binding Lectin | 1 | 2013 | 146 | 0.100 |
Why?
|
| Breast Neoplasms, Male | 1 | 2014 | 221 | 0.100 |
Why?
|
| Delivery of Health Care | 5 | 2023 | 5331 | 0.100 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2014 | 263 | 0.100 |
Why?
|
| Cost of Illness | 1 | 2002 | 1936 | 0.100 |
Why?
|
| Energy Intake | 5 | 2021 | 2127 | 0.100 |
Why?
|
| Peripartum Period | 2 | 2023 | 137 | 0.100 |
Why?
|
| Medication Systems | 1 | 2011 | 31 | 0.100 |
Why?
|
| Neopterin | 2 | 2023 | 56 | 0.100 |
Why?
|
| Boston | 9 | 2020 | 9304 | 0.100 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2012 | 190 | 0.100 |
Why?
|
| Health | 1 | 2014 | 398 | 0.100 |
Why?
|
| Exercise Tolerance | 1 | 2016 | 830 | 0.090 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2011 | 81 | 0.090 |
Why?
|
| ROC Curve | 4 | 2018 | 3563 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 1890 | 0.090 |
Why?
|
| Glycine | 1 | 2014 | 662 | 0.090 |
Why?
|
| History, 15th Century | 1 | 2010 | 29 | 0.090 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2018 | 1110 | 0.090 |
Why?
|
| Chromosome Aberrations | 2 | 2015 | 1763 | 0.090 |
Why?
|
| History, Medieval | 1 | 2010 | 62 | 0.090 |
Why?
|
| Endoscopy | 2 | 2018 | 1834 | 0.090 |
Why?
|
| Pharyngeal Diseases | 1 | 2012 | 134 | 0.090 |
Why?
|
| Killer Cells, Natural | 2 | 1998 | 2201 | 0.090 |
Why?
|
| History, 16th Century | 1 | 2010 | 70 | 0.090 |
Why?
|
| Sulfonylurea Compounds | 1 | 2012 | 219 | 0.090 |
Why?
|
| Germ-Line Mutation | 3 | 2014 | 1840 | 0.090 |
Why?
|
| Sleep | 3 | 2023 | 4744 | 0.090 |
Why?
|
| Carcinogens | 1 | 2013 | 451 | 0.090 |
Why?
|
| History, 17th Century | 1 | 2010 | 107 | 0.090 |
Why?
|
| Models, Statistical | 3 | 2020 | 5070 | 0.090 |
Why?
|
| Advisory Committees | 1 | 2015 | 785 | 0.090 |
Why?
|
| Medical Informatics | 1 | 2018 | 732 | 0.090 |
Why?
|
| Terminal Care | 1 | 2022 | 1750 | 0.090 |
Why?
|
| Esophageal Stenosis | 1 | 2012 | 192 | 0.090 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2011 | 122 | 0.090 |
Why?
|
| Nutritional Status | 2 | 2017 | 1607 | 0.090 |
Why?
|
| Databases, Genetic | 3 | 2022 | 1737 | 0.090 |
Why?
|
| Sensitivity and Specificity | 8 | 2022 | 14641 | 0.090 |
Why?
|
| Anemia | 2 | 2010 | 1504 | 0.090 |
Why?
|
| Case Management | 1 | 2012 | 273 | 0.090 |
Why?
|
| History, 18th Century | 1 | 2010 | 207 | 0.090 |
Why?
|
| Hematinics | 2 | 2010 | 280 | 0.090 |
Why?
|
| Environmental Exposure | 2 | 2024 | 4412 | 0.090 |
Why?
|
| Equipment Failure | 1 | 2012 | 578 | 0.090 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2012 | 849 | 0.090 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2016 | 1136 | 0.090 |
Why?
|
| Smoking Cessation | 4 | 2021 | 2055 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2010 | 125 | 0.080 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2011 | 213 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 2 | 2024 | 70 | 0.080 |
Why?
|
| Waist-Hip Ratio | 3 | 2019 | 516 | 0.080 |
Why?
|
| Receptors, Fc | 1 | 2013 | 534 | 0.080 |
Why?
|
| Syncope | 1 | 2012 | 427 | 0.080 |
Why?
|
| Neuropsychological Tests | 5 | 2019 | 7021 | 0.080 |
Why?
|
| Prostatic Secretory Proteins | 1 | 2009 | 24 | 0.080 |
Why?
|
| Xanthophylls | 4 | 2008 | 94 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2010 | 193 | 0.080 |
Why?
|
| Gastric Fistula | 1 | 1990 | 73 | 0.080 |
Why?
|
| Demography | 2 | 2012 | 1651 | 0.080 |
Why?
|
| Pulmonary Embolism | 1 | 2023 | 2540 | 0.080 |
Why?
|
| Intestinal Fistula | 1 | 1990 | 143 | 0.080 |
Why?
|
| Treatment Failure | 2 | 2012 | 2640 | 0.080 |
Why?
|
| Aromatase | 1 | 2009 | 147 | 0.080 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2018 | 2248 | 0.080 |
Why?
|
| Fibrinogen | 1 | 2012 | 883 | 0.080 |
Why?
|
| Pleural Diseases | 1 | 1990 | 137 | 0.080 |
Why?
|
| Apolipoproteins | 3 | 2023 | 319 | 0.080 |
Why?
|
| Endostatins | 1 | 2009 | 168 | 0.080 |
Why?
|
| Lipase | 2 | 2022 | 324 | 0.080 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2004 | 3755 | 0.080 |
Why?
|
| Animals | 22 | 2024 | 167768 | 0.080 |
Why?
|
| Sample Size | 2 | 2010 | 838 | 0.080 |
Why?
|
| Subarachnoid Hemorrhage | 3 | 2014 | 1031 | 0.080 |
Why?
|
| Calcium | 4 | 2022 | 5721 | 0.080 |
Why?
|
| Research Personnel | 1 | 2013 | 582 | 0.080 |
Why?
|
| Comparative Effectiveness Research | 2 | 2011 | 715 | 0.080 |
Why?
|
| Calcium, Dietary | 2 | 2001 | 529 | 0.080 |
Why?
|
| Cardiomyopathy, Alcoholic | 1 | 2008 | 6 | 0.080 |
Why?
|
| Schizophrenic Psychology | 1 | 2016 | 1646 | 0.080 |
Why?
|
| Morbidity | 2 | 2007 | 1754 | 0.080 |
Why?
|
| Defibrillators, Implantable | 1 | 2018 | 1487 | 0.080 |
Why?
|
| Vitamin D Deficiency | 1 | 2018 | 1377 | 0.080 |
Why?
|
| Gene Regulatory Networks | 2 | 2021 | 1740 | 0.080 |
Why?
|
| Endothelium, Vascular | 5 | 2011 | 4429 | 0.080 |
Why?
|
| Colonic Diseases | 1 | 1990 | 200 | 0.080 |
Why?
|
| Leptin | 1 | 2016 | 1591 | 0.080 |
Why?
|
| Quadriplegia | 1 | 1990 | 226 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2009 | 276 | 0.080 |
Why?
|
| Fistula | 1 | 1990 | 214 | 0.080 |
Why?
|
| Causality | 2 | 2012 | 1241 | 0.080 |
Why?
|
| Health Status Indicators | 3 | 2009 | 970 | 0.080 |
Why?
|
| History, 19th Century | 1 | 2010 | 720 | 0.080 |
Why?
|
| Periodicals as Topic | 2 | 2011 | 1462 | 0.080 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2020 | 3384 | 0.080 |
Why?
|
| Recurrence | 4 | 2016 | 8426 | 0.080 |
Why?
|
| Dinucleotide Repeats | 1 | 2007 | 29 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 1797 | 0.070 |
Why?
|
| New England | 1 | 2011 | 1053 | 0.070 |
Why?
|
| Resistin | 1 | 2008 | 172 | 0.070 |
Why?
|
| American Heart Association | 1 | 2012 | 1039 | 0.070 |
Why?
|
| Fragaria | 1 | 2007 | 21 | 0.070 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2007 | 99 | 0.070 |
Why?
|
| Alcohol Dehydrogenase | 2 | 2014 | 111 | 0.070 |
Why?
|
| Nutrition Surveys | 2 | 2021 | 1716 | 0.070 |
Why?
|
| Adolescent | 11 | 2019 | 87892 | 0.070 |
Why?
|
| Attitude to Health | 2 | 2014 | 2026 | 0.070 |
Why?
|
| Fibrinolytic Agents | 3 | 2005 | 2071 | 0.070 |
Why?
|
| Poultry | 2 | 2024 | 81 | 0.070 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2017 | 1214 | 0.070 |
Why?
|
| Lipid Peroxidation | 3 | 1998 | 271 | 0.070 |
Why?
|
| Food Handling | 1 | 2007 | 155 | 0.070 |
Why?
|
| Sex Characteristics | 5 | 2022 | 2621 | 0.070 |
Why?
|
| Signal Transduction | 4 | 2021 | 23342 | 0.070 |
Why?
|
| Fluoroscopy | 4 | 2016 | 944 | 0.070 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2008 | 335 | 0.070 |
Why?
|
| Pacemaker, Artificial | 1 | 2012 | 808 | 0.070 |
Why?
|
| Receptors, Androgen | 2 | 2010 | 1077 | 0.070 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2015 | 916 | 0.070 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2006 | 56 | 0.070 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 3609 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2014 | 1539 | 0.070 |
Why?
|
| Genome, Human | 2 | 2021 | 4416 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2012 | 1573 | 0.070 |
Why?
|
| Adiposity | 4 | 2019 | 1858 | 0.070 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2007 | 213 | 0.070 |
Why?
|
| Coronary Angiography | 4 | 2017 | 4451 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 2017 | 1564 | 0.070 |
Why?
|
| Databases, Factual | 6 | 2021 | 7980 | 0.070 |
Why?
|
| Data Collection | 1 | 2015 | 3322 | 0.070 |
Why?
|
| Cystatin C | 1 | 2007 | 270 | 0.070 |
Why?
|
| Carbonated Beverages | 1 | 2007 | 209 | 0.070 |
Why?
|
| Health Promotion | 1 | 1998 | 2204 | 0.070 |
Why?
|
| Cholesterol Esters | 2 | 1997 | 73 | 0.070 |
Why?
|
| Depressive Disorder, Major | 1 | 2024 | 4745 | 0.070 |
Why?
|
| Cross-Over Studies | 2 | 2004 | 2048 | 0.070 |
Why?
|
| Phosphorus | 1 | 2007 | 335 | 0.070 |
Why?
|
| Insulin-Secreting Cells | 1 | 2013 | 896 | 0.070 |
Why?
|
| Factor Analysis, Statistical | 2 | 2021 | 999 | 0.060 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 1277 | 0.060 |
Why?
|
| Quality of Life | 3 | 2016 | 13285 | 0.060 |
Why?
|
| Asia | 2 | 2018 | 616 | 0.060 |
Why?
|
| Quality Control | 2 | 2020 | 825 | 0.060 |
Why?
|
| Sickness Impact Profile | 1 | 2007 | 298 | 0.060 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2012 | 867 | 0.060 |
Why?
|
| Medical Order Entry Systems | 1 | 2011 | 522 | 0.060 |
Why?
|
| Oxidation-Reduction | 3 | 1999 | 2221 | 0.060 |
Why?
|
| Organ Specificity | 2 | 2021 | 1955 | 0.060 |
Why?
|
| Migraine without Aura | 1 | 2006 | 82 | 0.060 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2020 | 2420 | 0.060 |
Why?
|
| Epigenesis, Genetic | 2 | 2016 | 3754 | 0.060 |
Why?
|
| Hyperinsulinism | 1 | 2008 | 400 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 5 | 2016 | 6068 | 0.060 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2008 | 488 | 0.060 |
Why?
|
| Propensity Score | 3 | 2020 | 1907 | 0.060 |
Why?
|
| Immunoglobulin E | 1 | 2011 | 1484 | 0.060 |
Why?
|
| Food, Fortified | 2 | 1996 | 189 | 0.060 |
Why?
|
| Chemical Warfare Agents | 1 | 2024 | 19 | 0.060 |
Why?
|
| Defoliants, Chemical | 1 | 2024 | 9 | 0.060 |
Why?
|
| Metformin | 1 | 2012 | 907 | 0.060 |
Why?
|
| 2,4,5-Trichlorophenoxyacetic Acid | 1 | 2024 | 15 | 0.060 |
Why?
|
| Weight Gain | 1 | 2015 | 2346 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2007 | 3991 | 0.060 |
Why?
|
| Likelihood Functions | 2 | 2008 | 987 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 2912 | 0.060 |
Why?
|
| Ibuprofen | 1 | 2006 | 229 | 0.060 |
Why?
|
| 2,4-Dichlorophenoxyacetic Acid | 1 | 2024 | 25 | 0.060 |
Why?
|
| Probability | 2 | 2007 | 2467 | 0.060 |
Why?
|
| Gene Expression | 3 | 2024 | 7583 | 0.060 |
Why?
|
| Myocardial Revascularization | 3 | 2007 | 792 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 3615 | 0.060 |
Why?
|
| Hydrotherapy | 1 | 2003 | 6 | 0.060 |
Why?
|
| Health Policy | 1 | 2016 | 2677 | 0.060 |
Why?
|
| Cerebral Arteries | 2 | 2005 | 492 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 320 | 0.060 |
Why?
|
| Allergens | 1 | 2011 | 1402 | 0.060 |
Why?
|
| Penetrance | 1 | 2005 | 388 | 0.060 |
Why?
|
| Genes, Neoplasm | 1 | 2005 | 370 | 0.060 |
Why?
|
| Systole | 2 | 2009 | 936 | 0.060 |
Why?
|
| Knowledge Bases | 1 | 2024 | 97 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 611 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2019 | 1632 | 0.060 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 3211 | 0.050 |
Why?
|
| Stents | 1 | 2015 | 3162 | 0.050 |
Why?
|
| Hyperhomocysteinemia | 1 | 2004 | 118 | 0.050 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2024 | 148 | 0.050 |
Why?
|
| Leg | 1 | 2008 | 1087 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 2010 | 1321 | 0.050 |
Why?
|
| Afghan Campaign 2001- | 1 | 2024 | 296 | 0.050 |
Why?
|
| Respiratory Therapy | 1 | 2003 | 125 | 0.050 |
Why?
|
| Hospitals, Veterans | 2 | 2004 | 395 | 0.050 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2008 | 565 | 0.050 |
Why?
|
| Xerostomia | 1 | 2003 | 94 | 0.050 |
Why?
|
| Edetic Acid | 1 | 2003 | 282 | 0.050 |
Why?
|
| Logical Observation Identifiers Names and Codes | 1 | 2022 | 16 | 0.050 |
Why?
|
| Indoles | 1 | 2011 | 1828 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2010 | 2205 | 0.050 |
Why?
|
| Heterozygote | 3 | 2018 | 2797 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 2359 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2024 | 8553 | 0.050 |
Why?
|
| Laminin | 1 | 2024 | 405 | 0.050 |
Why?
|
| Renal Dialysis | 2 | 2010 | 1786 | 0.050 |
Why?
|
| Streptokinase | 2 | 2000 | 186 | 0.050 |
Why?
|
| Thyroid Neoplasms | 1 | 2016 | 2332 | 0.050 |
Why?
|
| Superoxide Dismutase | 1 | 2005 | 593 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2011 | 1201 | 0.050 |
Why?
|
| Mucin-5B | 1 | 2022 | 147 | 0.050 |
Why?
|
| Mass Screening | 4 | 2012 | 5427 | 0.050 |
Why?
|
| Research Support as Topic | 1 | 2006 | 697 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 2307 | 0.050 |
Why?
|
| Pesticides | 1 | 2024 | 292 | 0.050 |
Why?
|
| Laryngectomy | 1 | 2003 | 243 | 0.050 |
Why?
|
| Voice Quality | 1 | 2003 | 226 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2013 | 20500 | 0.050 |
Why?
|
| Speech Production Measurement | 1 | 2001 | 96 | 0.050 |
Why?
|
| Allylamine | 1 | 2001 | 10 | 0.050 |
Why?
|
| Editorial Policies | 1 | 2006 | 456 | 0.050 |
Why?
|
| Type A Personality | 1 | 2001 | 24 | 0.050 |
Why?
|
| Lutein | 3 | 2008 | 122 | 0.050 |
Why?
|
| Genetic Pleiotropy | 1 | 2022 | 181 | 0.050 |
Why?
|
| Cyclin T | 1 | 2021 | 19 | 0.050 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2008 | 1431 | 0.050 |
Why?
|
| Interleukin-10 Receptor beta Subunit | 1 | 2021 | 15 | 0.050 |
Why?
|
| Interviews as Topic | 3 | 2010 | 2676 | 0.050 |
Why?
|
| Conflict of Interest | 1 | 2006 | 548 | 0.050 |
Why?
|
| Patient Dropouts | 1 | 2003 | 412 | 0.050 |
Why?
|
| Tea | 2 | 2003 | 284 | 0.050 |
Why?
|
| Protein Disulfide-Isomerases | 1 | 2023 | 207 | 0.050 |
Why?
|
| Communicable Diseases | 1 | 2010 | 877 | 0.050 |
Why?
|
| Diastole | 2 | 2000 | 781 | 0.050 |
Why?
|
| GATA5 Transcription Factor | 1 | 2020 | 18 | 0.050 |
Why?
|
| Haplotypes | 4 | 2009 | 2764 | 0.050 |
Why?
|
| Drug Costs | 2 | 2000 | 1178 | 0.050 |
Why?
|
| Yogurt | 1 | 2021 | 71 | 0.050 |
Why?
|
| Phospholipase C beta | 1 | 2020 | 49 | 0.050 |
Why?
|
| Pedigree | 1 | 2008 | 4578 | 0.050 |
Why?
|
| Tunica Media | 1 | 2001 | 112 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2005 | 851 | 0.050 |
Why?
|
| Lysophospholipase | 1 | 2020 | 65 | 0.050 |
Why?
|
| Heart Rate | 1 | 2012 | 4166 | 0.050 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2021 | 112 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 3425 | 0.050 |
Why?
|
| Population Groups | 1 | 2021 | 211 | 0.050 |
Why?
|
| Lung Diseases | 1 | 2011 | 1910 | 0.040 |
Why?
|
| Respiration Disorders | 1 | 2003 | 367 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 3 | 1997 | 1475 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2007 | 1206 | 0.040 |
Why?
|
| 4-Quinolones | 1 | 1999 | 25 | 0.040 |
Why?
|
| Vaccines, Inactivated | 1 | 2021 | 179 | 0.040 |
Why?
|
| Activities of Daily Living | 2 | 2022 | 2414 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2022 | 383 | 0.040 |
Why?
|
| Genetic Counseling | 1 | 2024 | 624 | 0.040 |
Why?
|
| Computational Biology | 3 | 2019 | 3502 | 0.040 |
Why?
|
| Portugal | 1 | 2020 | 91 | 0.040 |
Why?
|
| Interleukin-2 | 2 | 1997 | 1888 | 0.040 |
Why?
|
| Single-Blind Method | 2 | 2018 | 1570 | 0.040 |
Why?
|
| Hyperthermia, Induced | 1 | 2003 | 416 | 0.040 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2005 | 1156 | 0.040 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2019 | 49 | 0.040 |
Why?
|
| Gemfibrozil | 1 | 1999 | 30 | 0.040 |
Why?
|
| Tetracyclines | 1 | 1999 | 64 | 0.040 |
Why?
|
| Liver | 3 | 2020 | 7502 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2012 | 296 | 0.040 |
Why?
|
| Counseling | 2 | 2014 | 1541 | 0.040 |
Why?
|
| Diet, Atherogenic | 2 | 1996 | 92 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 5246 | 0.040 |
Why?
|
| Pyridoxic Acid | 1 | 2019 | 4 | 0.040 |
Why?
|
| Unified Medical Language System | 1 | 2019 | 89 | 0.040 |
Why?
|
| Uromodulin | 1 | 2019 | 44 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 2047 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2019 | 126 | 0.040 |
Why?
|
| Time | 1 | 2001 | 543 | 0.040 |
Why?
|
| DNA | 2 | 2013 | 7199 | 0.040 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2019 | 120 | 0.040 |
Why?
|
| Proteins | 1 | 2014 | 6026 | 0.040 |
Why?
|
| Thrombolytic Therapy | 2 | 2000 | 2060 | 0.040 |
Why?
|
| Drug-Eluting Stents | 2 | 2015 | 679 | 0.040 |
Why?
|
| Ampulla of Vater | 1 | 2019 | 149 | 0.040 |
Why?
|
| Patient Discharge | 2 | 2004 | 3433 | 0.040 |
Why?
|
| Bile Ducts | 1 | 2020 | 282 | 0.040 |
Why?
|
| Diuretics | 1 | 2022 | 610 | 0.040 |
Why?
|
| NAD | 1 | 2023 | 609 | 0.040 |
Why?
|
| Tunica Intima | 1 | 2001 | 459 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2019 | 169 | 0.040 |
Why?
|
| Factor V | 1 | 2019 | 167 | 0.040 |
Why?
|
| Ion Channels | 1 | 2023 | 1043 | 0.040 |
Why?
|
| Gene Expression Regulation | 3 | 2021 | 11892 | 0.040 |
Why?
|
| Nutrition Assessment | 2 | 2015 | 726 | 0.040 |
Why?
|
| Genetic Testing | 2 | 2024 | 3530 | 0.040 |
Why?
|
| Medicare | 3 | 2023 | 6741 | 0.040 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2020 | 177 | 0.040 |
Why?
|
| Respiratory Muscles | 1 | 2018 | 142 | 0.040 |
Why?
|
| Computer Simulation | 2 | 2022 | 6201 | 0.040 |
Why?
|
| Pharmacoepidemiology | 1 | 2021 | 350 | 0.040 |
Why?
|
| Current Procedural Terminology | 1 | 2018 | 90 | 0.040 |
Why?
|
| Intensive Care Units | 2 | 2021 | 3732 | 0.040 |
Why?
|
| Mutation, Missense | 2 | 2023 | 2564 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1999 | 410 | 0.040 |
Why?
|
| Patient Participation | 1 | 2007 | 1436 | 0.040 |
Why?
|
| Potassium | 1 | 2022 | 1310 | 0.040 |
Why?
|
| Self-Injurious Behavior | 1 | 2024 | 556 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 1999 | 415 | 0.040 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2003 | 491 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 2 | 2000 | 1373 | 0.040 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 1994 | 1486 | 0.040 |
Why?
|
| Drug Labeling | 1 | 2000 | 248 | 0.040 |
Why?
|
| Pancreatitis, Chronic | 1 | 2020 | 281 | 0.040 |
Why?
|
| Caffeine | 2 | 2015 | 701 | 0.040 |
Why?
|
| Length of Stay | 1 | 2011 | 6439 | 0.040 |
Why?
|
| Apolipoproteins E | 1 | 2023 | 1436 | 0.040 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2012 | 3216 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2010 | 4938 | 0.040 |
Why?
|
| China | 2 | 2013 | 2333 | 0.040 |
Why?
|
| Apolipoproteins B | 1 | 2018 | 385 | 0.040 |
Why?
|
| Creatine Kinase | 1 | 1999 | 686 | 0.030 |
Why?
|
| Nutrition Policy | 1 | 2001 | 470 | 0.030 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 1996 | 61 | 0.030 |
Why?
|
| Kidney Tubules | 1 | 2018 | 449 | 0.030 |
Why?
|
| Interferon-gamma | 2 | 2023 | 3156 | 0.030 |
Why?
|
| Video Recording | 2 | 2015 | 954 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2020 | 675 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2007 | 4711 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 1997 | 310 | 0.030 |
Why?
|
| Aconitic Acid | 1 | 2016 | 13 | 0.030 |
Why?
|
| Public Health | 2 | 2023 | 2658 | 0.030 |
Why?
|
| Clinical Trials as Topic | 3 | 2014 | 7985 | 0.030 |
Why?
|
| Death, Sudden | 1 | 2018 | 302 | 0.030 |
Why?
|
| Isocitrates | 1 | 2016 | 23 | 0.030 |
Why?
|
| Muscular Diseases | 1 | 2020 | 551 | 0.030 |
Why?
|
| Analysis of Variance | 3 | 2015 | 6234 | 0.030 |
Why?
|
| Telephone | 2 | 2012 | 625 | 0.030 |
Why?
|
| Nutritive Value | 1 | 2019 | 349 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2023 | 1927 | 0.030 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2017 | 272 | 0.030 |
Why?
|
| Pattern Recognition, Automated | 1 | 2022 | 994 | 0.030 |
Why?
|
| Veterans Disability Claims | 1 | 2015 | 24 | 0.030 |
Why?
|
| Weight Loss | 1 | 2007 | 2671 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 1999 | 865 | 0.030 |
Why?
|
| Collagen | 1 | 2024 | 2635 | 0.030 |
Why?
|
| MEDLINE | 1 | 2015 | 119 | 0.030 |
Why?
|
| Oils | 1 | 2015 | 56 | 0.030 |
Why?
|
| Syndrome | 1 | 2022 | 3262 | 0.030 |
Why?
|
| Spirometry | 1 | 2018 | 923 | 0.030 |
Why?
|
| Soybean Proteins | 1 | 2015 | 55 | 0.030 |
Why?
|
| Mental Recall | 1 | 2001 | 1208 | 0.030 |
Why?
|
| Hospital Mortality | 2 | 2007 | 5272 | 0.030 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 16886 | 0.030 |
Why?
|
| Barium Sulfate | 1 | 2015 | 180 | 0.030 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2022 | 1988 | 0.030 |
Why?
|
| Models, Biological | 2 | 2009 | 9460 | 0.030 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1996 | 562 | 0.030 |
Why?
|
| Suicide, Attempted | 1 | 2024 | 1383 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 2001 | 1419 | 0.030 |
Why?
|
| Dinoprost | 1 | 1995 | 138 | 0.030 |
Why?
|
| Particle Size | 1 | 1999 | 1641 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2024 | 2413 | 0.030 |
Why?
|
| Atlases as Topic | 1 | 2016 | 241 | 0.030 |
Why?
|
| Isoflavones | 1 | 2015 | 136 | 0.030 |
Why?
|
| Arachidonic Acids | 1 | 1995 | 294 | 0.030 |
Why?
|
| Dinoprostone | 1 | 1997 | 598 | 0.030 |
Why?
|
| Calcinosis | 1 | 2003 | 1467 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2021 | 927 | 0.030 |
Why?
|
| Biological Availability | 1 | 1995 | 390 | 0.030 |
Why?
|
| Hysterectomy | 1 | 2020 | 904 | 0.030 |
Why?
|
| Aortography | 1 | 2016 | 420 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 1995 | 613 | 0.030 |
Why?
|
| Abdomen | 1 | 2020 | 1129 | 0.030 |
Why?
|
| Registries | 3 | 2020 | 8175 | 0.030 |
Why?
|
| Drinking | 1 | 2015 | 199 | 0.030 |
Why?
|
| Orchitis | 1 | 2014 | 35 | 0.030 |
Why?
|
| Databases, Nucleic Acid | 1 | 2015 | 204 | 0.030 |
Why?
|
| Epididymitis | 1 | 2014 | 37 | 0.030 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2014 | 87 | 0.030 |
Why?
|
| Food | 1 | 2019 | 771 | 0.030 |
Why?
|
| Intestinal Absorption | 1 | 1995 | 400 | 0.030 |
Why?
|
| Klinefelter Syndrome | 1 | 2014 | 47 | 0.030 |
Why?
|
| Combined Modality Therapy | 3 | 2016 | 8530 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2015 | 551 | 0.030 |
Why?
|
| Mice, 129 Strain | 1 | 2014 | 372 | 0.030 |
Why?
|
| Muscle Relaxation | 1 | 1993 | 138 | 0.030 |
Why?
|
| Pentetic Acid | 1 | 1993 | 209 | 0.030 |
Why?
|
| Peroxides | 1 | 1993 | 73 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2000 | 1187 | 0.030 |
Why?
|
| Urban Population | 1 | 2001 | 2025 | 0.030 |
Why?
|
| Genetics, Population | 1 | 2018 | 929 | 0.030 |
Why?
|
| Gynecomastia | 1 | 2014 | 87 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2022 | 1704 | 0.030 |
Why?
|
| Laboratories | 1 | 2017 | 460 | 0.030 |
Why?
|
| Oxidants | 1 | 1993 | 169 | 0.030 |
Why?
|
| Musculoskeletal Diseases | 1 | 2019 | 595 | 0.030 |
Why?
|
| Acetylation | 1 | 2016 | 1060 | 0.030 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2015 | 239 | 0.030 |
Why?
|
| Proinsulin | 1 | 2013 | 135 | 0.030 |
Why?
|
| Steroid Hydroxylases | 1 | 2013 | 96 | 0.030 |
Why?
|
| Societies, Medical | 2 | 2015 | 3891 | 0.030 |
Why?
|
| Suicide | 1 | 2024 | 1599 | 0.030 |
Why?
|
| Thymidylate Synthase | 1 | 2012 | 74 | 0.030 |
Why?
|
| Palmitic Acid | 1 | 2013 | 149 | 0.030 |
Why?
|
| Ubiquinone | 1 | 1993 | 182 | 0.030 |
Why?
|
| Sarcosine Dehydrogenase | 1 | 2011 | 5 | 0.030 |
Why?
|
| Formate-Tetrahydrofolate Ligase | 1 | 2011 | 5 | 0.030 |
Why?
|
| Celiac Disease | 1 | 2020 | 822 | 0.030 |
Why?
|
| Aminohydrolases | 1 | 2011 | 18 | 0.030 |
Why?
|
| Methylenetetrahydrofolate Dehydrogenase (NADP) | 1 | 2011 | 17 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 1993 | 341 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2008 | 5484 | 0.030 |
Why?
|
| Amplified Fragment Length Polymorphism Analysis | 1 | 2011 | 10 | 0.020 |
Why?
|
| Osteoporotic Fractures | 1 | 2017 | 408 | 0.020 |
Why?
|
| Trace Elements | 1 | 2013 | 196 | 0.020 |
Why?
|
| Menopause | 1 | 2020 | 1639 | 0.020 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1996 | 747 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2022 | 2872 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2015 | 590 | 0.020 |
Why?
|
| Homozygote | 2 | 2011 | 1788 | 0.020 |
Why?
|
| Health Personnel | 3 | 2014 | 3312 | 0.020 |
Why?
|
| Discriminant Analysis | 1 | 2012 | 222 | 0.020 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2013 | 174 | 0.020 |
Why?
|
| Flavonols | 1 | 2011 | 83 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2020 | 2533 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 1610 | 0.020 |
Why?
|
| Hepatitis C | 1 | 2001 | 1579 | 0.020 |
Why?
|
| France | 1 | 2012 | 499 | 0.020 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 2850 | 0.020 |
Why?
|
| Ankle Brachial Index | 1 | 2012 | 159 | 0.020 |
Why?
|
| Bone Neoplasms | 2 | 2015 | 2531 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2015 | 961 | 0.020 |
Why?
|
| Alu Elements | 1 | 2011 | 115 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2019 | 3774 | 0.020 |
Why?
|
| Sweden | 1 | 2014 | 1376 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2015 | 631 | 0.020 |
Why?
|
| Mice | 4 | 2019 | 81101 | 0.020 |
Why?
|
| Pregnancy | 2 | 2023 | 29742 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 3142 | 0.020 |
Why?
|
| Population Surveillance | 2 | 2018 | 2606 | 0.020 |
Why?
|
| Metals | 1 | 2015 | 717 | 0.020 |
Why?
|
| Biological Transport | 1 | 1995 | 2084 | 0.020 |
Why?
|
| Aorta, Thoracic | 2 | 1994 | 1094 | 0.020 |
Why?
|
| Chromatin | 1 | 2022 | 2938 | 0.020 |
Why?
|
| Dilatation | 1 | 2012 | 307 | 0.020 |
Why?
|
| Carcinoma, Papillary | 1 | 2016 | 785 | 0.020 |
Why?
|
| Testis | 1 | 2014 | 794 | 0.020 |
Why?
|
| Shock, Cardiogenic | 1 | 2016 | 707 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2012 | 614 | 0.020 |
Why?
|
| Aorta | 1 | 1998 | 2037 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 4540 | 0.020 |
Why?
|
| Vaccination | 1 | 2022 | 3355 | 0.020 |
Why?
|
| Israel | 1 | 2012 | 721 | 0.020 |
Why?
|
| Iron Compounds | 1 | 2010 | 28 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 2379 | 0.020 |
Why?
|
| Aortic Diseases | 1 | 2016 | 735 | 0.020 |
Why?
|
| Glycosyltransferases | 1 | 2010 | 117 | 0.020 |
Why?
|
| Fats | 1 | 2010 | 99 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 2895 | 0.020 |
Why?
|
| Vascular Surgical Procedures | 1 | 2018 | 1470 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 2015 | 897 | 0.020 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2011 | 330 | 0.020 |
Why?
|
| Vasodilation | 1 | 1994 | 960 | 0.020 |
Why?
|
| Proteomics | 1 | 2023 | 3816 | 0.020 |
Why?
|
| Iron, Dietary | 1 | 2010 | 148 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2020 | 2980 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 940 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2010 | 866 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2022 | 5098 | 0.020 |
Why?
|
| Reproduction | 1 | 2014 | 646 | 0.020 |
Why?
|
| Depression | 2 | 2024 | 8057 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2011 | 480 | 0.020 |
Why?
|
| Trinucleotide Repeats | 1 | 2010 | 257 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 1526 | 0.020 |
Why?
|
| Testicular Neoplasms | 1 | 2015 | 801 | 0.020 |
Why?
|
| Contrast Media | 2 | 2015 | 5298 | 0.020 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2009 | 70 | 0.020 |
Why?
|
| Acute Disease | 1 | 2000 | 7225 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2015 | 1434 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2011 | 346 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 22003 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2015 | 1471 | 0.020 |
Why?
|
| Observation | 1 | 2010 | 311 | 0.020 |
Why?
|
| Epistasis, Genetic | 1 | 2011 | 350 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 1995 | 1386 | 0.020 |
Why?
|
| Heart | 1 | 2022 | 4382 | 0.020 |
Why?
|
| Peptic Ulcer | 1 | 1990 | 217 | 0.020 |
Why?
|
| Glioblastoma | 2 | 2015 | 3480 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2000 | 3099 | 0.020 |
Why?
|
| Rabbits | 4 | 1996 | 4772 | 0.020 |
Why?
|
| Platelet Aggregation | 1 | 2011 | 773 | 0.020 |
Why?
|
| Heme | 1 | 2010 | 313 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2015 | 2105 | 0.020 |
Why?
|
| Reoperation | 1 | 2018 | 4282 | 0.020 |
Why?
|
| Fish Oils | 1 | 2012 | 481 | 0.020 |
Why?
|
| Multienzyme Complexes | 1 | 2011 | 665 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2020 | 4485 | 0.020 |
Why?
|
| Colitis, Ulcerative | 1 | 2020 | 1919 | 0.020 |
Why?
|
| Crohn Disease | 1 | 2020 | 2275 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2010 | 493 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2009 | 534 | 0.020 |
Why?
|
| Dietary Fiber | 1 | 2011 | 759 | 0.020 |
Why?
|
| Palliative Care | 1 | 2022 | 3570 | 0.020 |
Why?
|
| Prednisone | 1 | 2012 | 1565 | 0.020 |
Why?
|
| Tachycardia, Ventricular | 1 | 2016 | 1297 | 0.020 |
Why?
|
| DNA Helicases | 1 | 2012 | 854 | 0.020 |
Why?
|
| Sucrose | 1 | 2007 | 156 | 0.020 |
Why?
|
| Child | 2 | 2010 | 79818 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2016 | 4257 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2009 | 412 | 0.020 |
Why?
|
| Self Care | 1 | 2012 | 794 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2022 | 9404 | 0.020 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2009 | 490 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1725 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 2015 | 1090 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 1997 | 5490 | 0.020 |
Why?
|
| Introns | 1 | 2009 | 978 | 0.020 |
Why?
|
| Climate | 1 | 2007 | 147 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2007 | 763 | 0.020 |
Why?
|
| Pneumonia | 1 | 2018 | 2129 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2016 | 3527 | 0.020 |
Why?
|
| Calcifediol | 1 | 2007 | 161 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 11709 | 0.020 |
Why?
|
| Models, Cardiovascular | 1 | 2011 | 972 | 0.020 |
Why?
|
| Nurses | 1 | 2016 | 2467 | 0.020 |
Why?
|
| Self Medication | 1 | 2006 | 117 | 0.020 |
Why?
|
| Coronary Circulation | 1 | 2011 | 1561 | 0.020 |
Why?
|
| Histones | 1 | 2016 | 2577 | 0.020 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2015 | 1402 | 0.020 |
Why?
|
| Calcitriol | 1 | 2007 | 297 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2021 | 3806 | 0.020 |
Why?
|
| Lipoproteins | 3 | 1996 | 881 | 0.020 |
Why?
|
| Informed Consent | 1 | 2012 | 1003 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2019 | 3261 | 0.020 |
Why?
|
| Cell Line | 1 | 2019 | 15591 | 0.020 |
Why?
|
| Death Certificates | 1 | 2006 | 167 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 3364 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2011 | 996 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2021 | 4652 | 0.020 |
Why?
|
| Risk Adjustment | 1 | 2009 | 600 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 1994 | 2131 | 0.020 |
Why?
|
| Sweetening Agents | 1 | 2007 | 290 | 0.020 |
Why?
|
| Albumins | 1 | 2007 | 575 | 0.010 |
Why?
|
| Environment | 1 | 2011 | 1118 | 0.010 |
Why?
|
| Echocardiography | 1 | 2017 | 4962 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2024 | 12094 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 1996 | 3047 | 0.010 |
Why?
|
| Selection Bias | 1 | 2006 | 357 | 0.010 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2015 | 1627 | 0.010 |
Why?
|
| Calcimycin | 2 | 1994 | 213 | 0.010 |
Why?
|
| gamma-Tocopherol | 1 | 2003 | 30 | 0.010 |
Why?
|
| Research | 2 | 2004 | 1976 | 0.010 |
Why?
|
| Puerto Rico | 1 | 2005 | 373 | 0.010 |
Why?
|
| Brassica | 1 | 2003 | 40 | 0.010 |
Why?
|
| Germany | 1 | 2005 | 868 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2007 | 1593 | 0.010 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2004 | 186 | 0.010 |
Why?
|
| Cytokines | 1 | 1998 | 7338 | 0.010 |
Why?
|
| Glucose Intolerance | 1 | 2007 | 575 | 0.010 |
Why?
|
| Malus | 1 | 2003 | 50 | 0.010 |
Why?
|
| Cost Savings | 1 | 2008 | 918 | 0.010 |
Why?
|
| Decision Making | 1 | 2016 | 3915 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2015 | 2276 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2018 | 18940 | 0.010 |
Why?
|
| Prostatectomy | 1 | 2011 | 1956 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2012 | 3441 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 1793 | 0.010 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2002 | 113 | 0.010 |
Why?
|
| Angioplasty | 1 | 2004 | 354 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2007 | 1745 | 0.010 |
Why?
|
| Acetylcholine | 2 | 1994 | 628 | 0.010 |
Why?
|
| Proteinuria | 1 | 2004 | 594 | 0.010 |
Why?
|
| Exons | 1 | 2007 | 2387 | 0.010 |
Why?
|
| Cholagogues and Choleretics | 1 | 2001 | 37 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 7818 | 0.010 |
Why?
|
| Genome | 1 | 2009 | 1739 | 0.010 |
Why?
|
| Seasons | 1 | 2007 | 1519 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2005 | 1514 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2021 | 26183 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 2001 | 283 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 2007 | 1501 | 0.010 |
Why?
|
| Qualitative Research | 1 | 2010 | 2976 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1997 | 10171 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2006 | 1504 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2012 | 3446 | 0.010 |
Why?
|
| Canada | 1 | 2005 | 2111 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1999 | 186 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2014 | 14354 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 18119 | 0.010 |
Why?
|
| Mutation | 2 | 2020 | 29915 | 0.010 |
Why?
|
| Laryngeal Neoplasms | 1 | 2002 | 514 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2003 | 1791 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 2008 | 2108 | 0.010 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 1997 | 60 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2000 | 15637 | 0.010 |
Why?
|
| Capsules | 1 | 1997 | 191 | 0.010 |
Why?
|
| Anistreplase | 1 | 1996 | 11 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 3617 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2004 | 2697 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 2638 | 0.010 |
Why?
|
| Mouth Neoplasms | 1 | 2002 | 593 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 2167 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1997 | 490 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 3480 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2003 | 2896 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2001 | 1686 | 0.010 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2004 | 973 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 1998 | 583 | 0.010 |
Why?
|
| Premedication | 1 | 1996 | 247 | 0.010 |
Why?
|
| Nitrates | 1 | 1996 | 263 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 11070 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2008 | 3245 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1996 | 677 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1996 | 1317 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 1998 | 918 | 0.010 |
Why?
|
| Nitroprusside | 1 | 1994 | 272 | 0.010 |
Why?
|
| Calcium Channel Blockers | 1 | 1996 | 694 | 0.010 |
Why?
|
| Methylation | 1 | 1996 | 1080 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 9273 | 0.010 |
Why?
|
| Magnesium | 1 | 1996 | 809 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1996 | 1154 | 0.010 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1996 | 776 | 0.010 |
Why?
|
| Femoral Artery | 1 | 1996 | 824 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1994 | 940 | 0.010 |
Why?
|
| Arteries | 1 | 1997 | 1125 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1997 | 1557 | 0.010 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1996 | 829 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1996 | 1240 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1996 | 1503 | 0.010 |
Why?
|
| Veins | 1 | 1994 | 765 | 0.010 |
Why?
|
| Heparin | 1 | 1996 | 1632 | 0.010 |
Why?
|
| Melanoma | 1 | 2007 | 5691 | 0.000 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1996 | 3527 | 0.000 |
Why?
|
| Radiography | 1 | 1996 | 6954 | 0.000 |
Why?
|
| Statistics as Topic | 1 | 1991 | 2359 | 0.000 |
Why?
|
| Brain | 1 | 2005 | 26947 | 0.000 |
Why?
|